Results 141 to 150 of about 4,378 (171)

Alkaline phosphatase decline and pain response as predictors of overall survival benefit in patients treated with radium-223: a post hoc analysis of the REASSURE study. [PDF]

Br J Cancer
O'Sullivan JM, Heinrich D, Castro E, George S, Dizdarevic S, Baldari S, Essler M, Jong IJ, Lastoria S, Hammerer PG, Tombal B, James ND, Meltzer J, Sandström P, Sartor O.   +14 more
europepmc   +1 more source

Joint Regional Uptake Quantification of Thorium-227 and Radium-223 Using a Multiple-Energy-Window Projection-Domain Quantitative SPECT Method. [PDF]

IEEE Trans Med Imaging
Li Z, Benabdallah N, Laforest R, Wahl RL, Thorek DLJ, Jha AK.   +5 more
europepmc   +1 more source

Synergistic Activity of DNA Damage Response Inhibitors in Combination with Radium-223 in Prostate Cancer. [PDF]

Cancers (Basel)
Dunne VL, Wright TC, Liberal FDCG, O'Sullivan JM, Prise KM.   +4 more
europepmc   +1 more source

Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer. [PDF]

Cancer Immunol Res
Choudhury AD, Kwak L, Cheung A, Allaire KM, Marquez J, Yang DD, Tripathi A, Kilar JM, Flynn M, Maynard B, Reichel R, Pace AF, Chen BK, Van Allen EM, Kilbridge K, Wei XX, McGregor BA, Pomerantz MM, Bhatt RS, Sweeney CJ, Bubley GJ, Jacene HA, Taplin ME, Huang FW, Harshman LC, Fong L.   +25 more
europepmc   +1 more source

Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer. [PDF]

JCO Precis Oncol
Saylor PJ, Otani K, Balza R, Ukleja J, Pleskow H, Fisher R, Kusaka E, Otani YS, Badusi PO, Smith MR, Meneely E, Olivier K, Lowe AC, Toner M, Maheswaran S, Haber DA, Yeap BY, Lee RJ, Miyamoto DT.   +18 more
europepmc   +1 more source

Radium-223 Treatment Produces Prolonged Suppression of Resident Osteoblasts and Decreased Bone Mineral Density in Trabecular Bone in Osteoblast Reporter Mice. [PDF]

Cancers (Basel)
Lin SC, Yu G, Corn PG, Damasco J, Lee YC, Song JH, Navone NM, Logothetis CJ, Melancon MP, Panaretakis T, Lin SH.   +10 more
europepmc   +1 more source

Survival outcomes of radium-223 therapy for metastatic castration-resistant prostate cancer following national health insurance reimbursement in Taiwan. [PDF]

J Chin Med Assoc
Yao SF, Huang WJ, Wei TC, Wang YF, Lin KH, Hu LH, Ting CH, Lee TH, Yeh SH, Peng NJ.   +9 more
europepmc   +1 more source

Case report: Exceptional and durable response to Radium-223 and suspension of androgen deprivation therapy in a metastatic castration-resistant prostate cancer patient. [PDF]

Front Oncol
Zacchi F, Carles J, Gonzalez M, Maldonado X, Perez-Lopez R, Semidey ME, Mateo J.   +6 more
europepmc   +1 more source

An objective measure of response on whole-body MRI in metastatic hormone sensitive prostate cancer treated with androgen deprivation therapy, external beam radiotherapy, and radium-223. [PDF]

Br J Radiol
Giacometti V, Grey AC, McCann AJ, Prise KM, Hounsell AR, McGarry CK, Turner PG, O'Sullivan JM.   +7 more
europepmc   +1 more source

Lymphocyte Function at Baseline Could Be a New Predictor of Tumor Burden following Six Cycles of Radium-223 Therapy in Patients with Metastasized, Castration-Resistant Prostate Cancer. [PDF]

Cancers (Basel)
Barsegian V, Möckel D, Buehler S, Müller SP, Kreissl MC, Ostheim P, Horn PA, Lindemann M.   +7 more
europepmc   +1 more source